ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Galapagos' BioFocus DPI chemistry services unit has entered a discovery deal with OneWorld Health, a nonprofit drug company based in San Francisco and backed by the Bill & Melinda Gates Foundation and other donors. BioFocus will apply its medicinal chemistry expertise to identify new drug candidates for OneWorld's diarrheal disease program. Galapagos says the pact is worth about $4 million over two-and-a-half years.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter